Long‐term efficacy of opicapone in fluctuating Parkinson's disease patients: a pooled analysis of data from two phase 3 clinical trials and their open‐label extensions

BACKGROUND AND PURPOSE: The aim was to evaluate the efficacy of the catechol‐O‐methyltransferase inhibitor opicapone (25 and 50 mg) as adjunct therapy to levodopa in a pooled population of Parkinson's disease patients who participated in the pivotal double‐blind trials of opicapone and their 1‐...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferreira, J. J., Lees, A., Rocha, J.‐F., Poewe, W., Rascol, O., Soares‐da‐Silva, P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593852/
https://www.ncbi.nlm.nih.gov/pubmed/30681754
http://dx.doi.org/10.1111/ene.13914

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593852/
https://www.ncbi.nlm.nih.gov/pubmed/30681754
http://dx.doi.org/10.1111/ene.13914

Ejemplares similares